


**Figure S1**



**Figure S1. The CNS axon injury model in *Drosophila* larvae and regeneration induced by glial overexpression of Pi3K92E<sup>CA</sup> and Egfr<sup>CA</sup>, related to Figure 1.**

(A) Schematic (left) and images (middle) show axons degenerating out of the neuropil at 8 h AI in both WT and larvae with glial overexpression of Pi3K92E<sup>CA</sup> and Egfr<sup>CA</sup>. Quantifications (right) show no difference in the percentage of axon bundle terminals out of the neuropil between the two groups (Fisher's exact test).

(B) Glial-scar-like tissue at 24 h AI in WT. Blue dotted circle demarcates the glial-scar-like region in the fluorescence images (right), and green autofluorescence indicates the lesion core which is located in the center of the glial-scar-like tissue. Electron microscopy (left) shows the hypertrophic glia in the glial-scar-like tissue. Axons (turquoise); Astrocytes (purple); Hypertrophic astrocytes (red). Scale bar: 1  $\mu$ m.

(C) Left, axon degeneration at 8 h AI and regeneration at 24 and 48 h AI of C4da neurons in the VNC in both WT and larvae with glial overexpression of Pi3K92E<sup>CA</sup> and Egfr<sup>CA</sup>. Regenerated axons are in red in the neuropil (demarcated by the orange dashed lines), and the red dotted circles show the injury sites. Right, graphs show that, at 24 h AI, there is no difference in the percentage of axon bundle terminals reaching the neuropil between the two groups (Fisher's exact test).

(D) Quantification of normalized regenerated axon length for genotypes and time points presented in (C), n for WT = 44, 62, 18 and n for Pi3K92E<sup>CA</sup> + Egfr<sup>CA</sup> = 70, 32, 20 lesioned segments, two-way ANOVA with Tukey's test.

(E) Quantification of regeneration percentage for genotypes and time points presented in (C), Fisher's exact test.


(F) Images show ddaF (Class III da neuron) regeneration in the PNS of control (*repo-Gal4, UAS-mRFP; NompC-QF, QUAS-mCD8GFP*) and larvae with glial overexpression of Pi3K92E<sup>CA</sup> and Egfr<sup>CA</sup>. Class III da neuron are labelled by *NompC-QF > mCD8GFP*. The red dotted circles show the injury sites and the red arrows indicate axon tips. Injury is confirmed at 24 hours AI and regeneration is assessed at 72 hours AI.

(G) Quantification of normalized regenerated axon length for genotypes presented in panel (F), unpaired two-tailed Student's t-test.

(H) Quantification of regeneration percentage for genotypes presented in panel (F), Fisher's exact test.

Scale bars, 20  $\mu$ m (unless indicated otherwise). Data are expressed as mean  $\pm$  s.e.m.

**Figure S2**



**Figure S2. Quantification of CNS axon regeneration, related to Figure 1, 3, 4, 5, 6 and STAR Methods.**

(A) For each larvae, 2 photons laser induced lesion is on the A3 and A6 segments (red dotted rectangle).

(B) To quantify regeneration length, the length of regenerated axons inside the neuropil (red lines indicate regenerated axon and the neuropil is demarcated by the orange dashed lines) of injured bundles from both-sides are measured. Their sum (as L1 + L2 shown in the schematics) is normalized by the distance between the A4 and A5 segments (white line in (A)).


(C) Samples of axon regeneration length quantification for WT and glial overexpression of  $Pi3K92E^{CA}$  and  $Egfr^{CA}$  following the rules depicted in (B).

(D) Quantification of regeneration percentage. The two black dotted lines mark the location of C4da neuron axon terminals. Regenerated axons that extend into this region are more likely to contribute to functional recovery and are thus considered as regenerated (the regenerated axon on the left is regarded as regenerated, but not the one on the right). For each segment, as long as one axon has regenerated, it is regarded as a regenerated lesioned segment.

(E) Quantification of normalized regenerated axon length of C4da neurons in flies with “*ppk-CD4tdGFP*” (used for labelling C4da neurons), “*ppk-CD4tdGFP; repo-Gal4*”, “*ppk-CD4tdGFP; alrm-Gal4*”, “*ppk-CD4tdGFP; TIFR-Gal4*”, “*ppk-CD4tdGFP; GMR54H02-Gal4*” and the WT group (*ppk-CD4tdGFP; repo-Gal4, UAS-mRFP*). n = 16, 22, 20, 20, 20, 62 lesioned segments from 8, 11, 10, 10, 10, 31 larvae respectively for each genotype, one-way ANOVA with Dunnett’s test.

(F) Quantification of regeneration percentage for genotypes in (E), Fisher’s exact test.

**Figure S3**



**Figure S3. Reprogramming glial cells promotes functional recovery after injury in the *Drosophila* CNS, related to Figure 2.**


(A) Behavioral tests on uninjured larvae from WT or glial overexpression of Pi3K92E<sup>CA</sup>, Egfr<sup>CA</sup> (one-way ANOVA with Tukey's test).

(B) Behavioral tests on injured larvae from WT or glial overexpression of Pi3K92E<sup>CA</sup>, Egfr<sup>CA</sup> at 8 h, 24 h and 48 h AI. Tests on A4 and A5 are the positive control (two-way ANOVA).

(C) Behavioral scores of tests on A4 and A5 of larvae shown in **Figure 2D**.

Data are expressed as mean  $\pm$  s.e.m.

Figure S4



**Figure S4. Glycolysis is critical for axon regeneration in the CNS induced by reprogramming glial cells, related to Figure 3, 4.**

(A, B) RNA sequencing analysis of CNS tissues collected from control (*repo-Gal4, UAS-mRFP*) or glial overexpression of *Pi3K92E<sup>CA</sup>* and *Egfr<sup>CA</sup>*. Heat map (A) shows significantly differentially expressed genes (DEGs = 2403, fold-change > 2, probability of equally expressed < 0.05) from the two groups (two individual experiments for each group, 70-100 larvae CNS tissues for each experiment). GO analysis of DEGs (B).

(C, D) Normalized regenerated axon length (C) and regeneration percentage (D) of flies with glial *CG9399* or *CG9396* RNAis, and WT as control, n = 62, 26, 26 lesioned segments for each genotype; regeneration length, one-way ANOVA with Dunnett's test, adjusted *P* value showed in graphs; regeneration percentage, Fisher's exact test.

(E, F) Normalized regenerated axon length (E) and regeneration percentage (F) of flies with glial *sima* RNAis (two RNAis) in the *repo-Gal4>Pi3K92E<sup>CA</sup>, Egfr<sup>CA</sup>* background at 24 h AI, with glial mCherry expression as control (*UAS-mCherry; repo-Gal4, UAS-Pi3K92E<sup>CA</sup>, UAS-Egfr<sup>CA</sup>; ppk-CD4tdGFP*), n = 28, 20, 22 lesioned segments for each genotype; regeneration length, one-way ANOVA with Dunnett's test, adjusted *P* value showed in graphs; regeneration percentage, Fisher's exact test.

(G, H) Normalized regenerated axon length (G) and regeneration percentage (H) of flies with glial *out* RNAis (two RNAis) in the *repo-Gal4>Pi3K92E<sup>CA</sup>, Egfr<sup>CA</sup>* background at 24 h AI, with glial mCherry expression as control (*UAS-mCherry; repo-Gal4, UAS-Pi3K92E<sup>CA</sup>, UAS-Egfr<sup>CA</sup>; ppk-CD4tdGFP*), n = 28, 30, 26 lesioned segments for each genotype; regeneration length, one-way ANOVA with Dunnett's test, adjusted *P* value showed in graphs; regeneration percentage, Fisher's exact test.

(I, J) Chiral derivatization was performed to allow separation of enantiomers for 2HG (I) and lactate (J) by liquid chromatography-mass spectrometry (LC-MS). The graphs show separated spikes of mixed reference standards of L-2HG and D-2HG, or L-lactate and D-lactate.

(K) Ratio of L-lactate/pyruvate in the WT and *repo-Gal4>Pi3K92E<sup>CA</sup>, Egfr<sup>CA</sup>* groups. Metabolites are measured from the CNS tissues of fly larvae and each data point represents one experiment using 50-100 larval CNS tissues (unpaired two-tailed Student's *t*-test).




(L) Concentrations of metabolites in the hemolymph samples of WT larvae measured by gas chromatography-mass spectrometry (GC-MS) or LC-MS.

(M) Quantification of fluorescence intensity ratio of mTFP/Venus from glial cells in the VNC of flies expressing glial Laconic (*repo-Gal4, UAS-Laconic*). VNCs were treated with PBS, sodium lactate (160 mM) or lactate mixture (140 mM sodium L-lactate + 20 mM ethyl L-lactate) for 40 minutes *in vitro* (one-way ANOVA with Dunnett's test, adjusted *P* value showed in graphs).

Data are expressed as mean  $\pm$  s.e.m.

Figure S5




**Figure S5. L-tartrate is not a viable energy source for *Drosophila* larvae, and axon regeneration of C4da neurons with neuronal *Sln* or *out* RNAis when glia is reprogrammed by Myc, related to Figure 5 and Discussion.**

(A) Survival rate of *w<sup>1118</sup>* larvae fed with water, sucrose, L-lactate or L-tartrate (n = 40 for each group).

(B) Quantification of normalized regenerated axon length in flies with *ppk-Gal4* as control (*ppk-Gal4; repo-QF, QUAS-Myc; ppk-CD4tdGFP*), C4da neuronal *Sln* RNAis and *out* RNAis, in the background of *repo-QF>Myc*, two RNAis for each gene knockdown, n = 28, 16, 14, 16, 16 lesioned segments from 14, 8, 7, 8, 8 larvae respectively for each genotype, one-way ANOVA with Dunnett' s test.

(C) Quantification of regeneration percentage for genotypes in (B), Fisher's exact test.

**Figure S6**



**Figure S6. Axon regeneration induced by reprogramming glial cells depends on GABA<sub>B</sub> receptor in C4da neurons, and L-lactate and L-2HG regulate cAMP level in neurons through GABA<sub>B</sub> receptor, related to Figure 6.**

(A) Normalized regenerated axon length for flies with RNAis targeting screened candidates possibly interacting with L-lactate in neurons in the *repo-QF>Myc* background (control: *ppk-Gal4; repo-QF, QUAS-Myc; ppk-CD4tdGFP*), n = 28, 6, 22, 12, 16, one-way ANOVA with Dunnett's test, adjusted *P* value shown in graphs.

(B) Schematics showing the MiMIC insertion in *GABA-B-R1*<sup>MI03255</sup>. Primers spanning exons 15 and 16 are used in (C) to detect the transcript level of *GABA-B-R1*.

(C) *GABA-B-R1* transcription is reduced in *GABA-B-R1*<sup>MI03255</sup> mutants. PCR templates are cDNA derived from homogenized whole larvae. *Ribosomal protein 49 (rp49)* is used as loading control (n = 3 replicates).

(D) Quantification of normalized regenerated axon length of C4da neurons in flies with glial mCherry expression as control (*UAS-mCherry; repo-Gal4, UAS-Pi3K92E<sup>CA</sup>, UAS-Egfr<sup>CA</sup>; ppk-CD4tdGFP*), glial *GABA-B-R1* RNAis and glial *GABA-B-R2* RNAis in the *repo-Gal4>Pi3K92E<sup>CA</sup>, Egfr<sup>CA</sup>* background at 24 h AI in the VNC. Two RNAis for each gene knockdown, n = 28, 20, 24, 20, 22 lesioned segments from 14, 10, 12, 10, 11 larvae for each genotype respectively, one-way ANOVA with Dunnett's test.

(E) Quantification of regeneration percentage for genotypes in (D), Fisher's exact test.


(F) *GABA-B-R1* is labeled by *GABA-B-R1*<sup>MI01930-GFSTF.0</sup>, a GFP-tagged *GABA-B-R1* allele, and C4da neuron axons are labeled by *ppk-CD4tdTomato*. VNC is demarcated by the white line.

(G) Representative images for data in **Figure 6I**.

(H) GABA-B receptor activation by SKF97541 (agonist for GABA-B receptor) at a concentration range from 0.00001-1 mM, which is revealed by <sup>35</sup>S-GTPγS assay for G protein coupled receptors with Human recombinant GABBR1a and GABBR2. Activation by SKF97541 is defined as positive. X-axis shows as Log10.

Scale bars, 20μm. Data are expressed as mean ± s.e.m.

**Figure S7**



**Figure S7. GFAP and ALDH1L1 staining at the lesion site, and expression of Gabbr1 and Gabbr2 in different cell types of murine CNS and its correlation with the axon regeneration potential, related to Figure 7.**

(A) Quantification of GFAP staining area at the lesion site from the lactate treatment and saline control groups. Red dash line demarcates the astrocyte scar boarder and yellow dash line demarcates reactive astrocytes in spared but reactive neural tissue. Scale bar, 200  $\mu$ m.

(B) ALDH1L1 staining at the lesion site of the lactate treatment and saline control groups. Scale bar, 200  $\mu$ m.

(C) Gene expression of Gabbr1 and Gabbr2 from Mouse Whole Cortex and Hippocampus SMART-seq (the Allen mouse brain atlas, calculated as trimmed means), including all non-neuronal clusters and representative 10 neuronal clusters.

(D) Gene expression of Gabbr1 and Gabbr2 in astrocytes and microglia in mice of different ages from a previous study (Gene Expression Omnibus (GEO) accession code GSE137028, calculated as FPKM (fragments per kilobase of exon model per million reads mapped)). M, month.

(E) Gene expression ratio of Gabbr2 to Gabbr1 in astrocytes from spinal cord, cerebellum, cerebral cortex and hippocampus from a previous study (GSE100329).

(F) Gene expression ratio of Gabbr2 to Gabbr1 in astrocytes from spinal cord before and after SCI from a previous study (GSE76097).

(G) Gene expression ratio of Gabbr2 to Gabbr1 in CST neurons before and after SCI from a previous study (GSE126957).

(H) Quantification of mean fluorescence intensity of Gabbr2 and Gabbr1 in CST axons within an area around the lesion site (0.8 mm rostral and caudal to the lesion center), from the lactate treatment group (n = 4 mice) and saline control group (n = 3 mice). The representative images show Gabbr2 staining with BDA-labelled CST axons in the two groups. Two-tailed unpaired student's t-test. Scale bar, 200  $\mu$ m.

(I) Gene expression of Gabbr1 and Gabbr2 in response to different severity of SCI from a previous study (GSE115067).

(J) Gene expression of Gabbr1 and Gabbr2 in CST neurons after SCI. Regenerating group refers to regenerated axons induced by neural progenitor cell grafts; non regenerating group refers to lesion only (GSE126957).

**Table S1**

<i>ppk-CD4tdGFP; repo-Gal4&gt;</i>	Human homologs	Regeneration percentage (%)	<i>p</i> value, n (vs. WT, n =62 9.7%)
<i>Pi3K92E<sup>CA</sup></i>	<i>PI3K</i>	66.7	<0.0001, 24
<i>Egfr<sup>CA</sup></i>	<i>EGFR</i>	54.5	<0.0001, 22
<i>stg</i>	<i>CDC25A</i>	52.6	<0.0001, 19
<i>btl<sup>CA</sup></i>	<i>FGFR1</i>	44.4	0.0006, 18
<i>htl<sup>CA</sup></i>	<i>FGFR3</i>	42.3	0.0004, 26
<i>sima</i>	<i>HIF1A</i>	43.8	0.0011, 16
<i>ci</i>	<i>GLI3</i>	42.9	0.0021, 14
<i>foxo</i>	<i>FOXO1</i>	42.9	0.0021, 14
<i>Smox</i>	<i>SMAD3</i>	41.7	0.0044, 12
<i>Stat92E</i>	<i>STAT5</i>	35.7	0.0124, 14
<i>p53<sup>DN</sup></i>	<i>TP53</i>	30	0.0714, 10
<i>Grn</i>	<i>GATA2</i>	16.7	0.4754, 12
<i>Su(H)</i>	<i>RBPJ</i>	0	0.17, 18



**Table S1.** List of genes screened for axon regeneration in the CNS when they are expressed in glial cells (Fisher's exact test). CA, constitutively active; DN, dominant negative. Related to Figure 1.